
“The addition of SKY-AS marks an important evolution for Skylark as we expand beyond hearing loss into serious neurological disorders with substantial unmet need." businesswire.com/news/home/2…

Maguire Lab In vivo gene delivery developer

“The addition of SKY-AS marks an important evolution for Skylark as we expand beyond hearing loss into serious neurological disorders with substantial unmet need." businesswire.com/news/home/2…

I am so proud of the Skylark Team For bringing this potential treatment to patients!


13% success rates for FY2025. NIH finally releases some FY2025 success rate data drugmonkey.wordpress.com/202… via @drugmonkeyblog

Some context for the UniQure $QURE post below: Earlier today, the FDA held a media call with the same "senior FDA official" who spoke to me (and other reporters) individually earlier in the week. The call was set up obstensibly so that this senior FDA official could rail against UniQure without going on the record. He did exactly this for 30 minutes, repeating the same criticisms, claiming Uniqure's Huntington’s therapy is a failure, the sham surgery would be blinded even if just small "nicks" in the skin were made in a 30-minute procedure, dismissing the idea of formally reviewing the therapy, disregarding outside scientific experts, and then accusing the media of not adequately covering what the FDA (and this official) have been doing. Reporters from Bloomberg, STAT, NY Times, WSJ, Politico and other media organizations were on the call.
uniQure@uniQure_NV Mar 6


It never ceases to shock me that not every single person knows about the gene therapy trials that restored hearing in congenitally deaf children. In fact, not a single one of my cell bio students in lecture tonight knew about this triumph of science and medicine!!! 🤯🤯🤯


Useful summary of how much has changed this year with NIH/NSF funding. nytimes.com/interactive/2025…

“I had hemophilia for nearly five decades. I went to Philadelphia and had a 45-minute infusion, and my hemophilia was gone.” Genes-> Medicine @NatureMedicine nature.com/articles/s41591-0…

Efficient Scaling up EV‐AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy - Yan - 2025 - Journal of Extracellular Vesicles - Wiley Online Library isevjournals.onlinelibrary.w…

Extracellular Vesicles-Associated AAVs for the treatment of Machado-Joseph Disease dlvr.it/TNcSNm #genetherapy #celltherapy

In a new study, researchers from @CGM_MGH and colleagues found that a customized gene-editing technology shows potential to treat lethal pediatric disease. The study was published in @natBME. Read more: massgeneralbrigham.org/en/ab… @BKleinstiver @MGBInnovation

Congratulations to all co-authors! And here is a free link to access the manuscript: rdcu.be/eFAEz

Our manuscript describing the optimization of a bespoke base editor to treat a severe pediatric vascular disease is now published in @natBME 🫀🧬 See my previous Xtorial below for details about this massive collaborative effort nature.com/articles/s41551-0…
Check out our @biorxivpreprint describing our efforts to treat a severe vascular disease 🫀: 1️⃣ Optimization of a target-specific base editor🧬 2⃣ A *must avoid* bystander edit prevalent with WT SpCas9 BEs! 🙅♂️😱 3⃣ Substantial extension of lifespan following in vivo base editing! 🐁✅ A 🧵 below with more details! @CGM_MGH @MGH_RI @MassGeneralNews @harvardmed biorxiv.org/content/10.1101/…

Next Generation AAV-F Capsid gene therapy rescues disease pathology in a model of Pyruvate Dehydrogenase Complex Deficiency biorxiv.org/content/10.1101/…